These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 29959809)
1. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Hida T; Seto T; Horinouchi H; Maemondo M; Takeda M; Hotta K; Hirai F; Kim YH; Matsumoto S; Ito M; Ayukawa K; Tokushige K; Yonemura M; Mitsudomi T; Nishio M Cancer Sci; 2018 Sep; 109(9):2863-2872. PubMed ID: 29959809 [TBL] [Abstract][Full Text] [Related]
2. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779 [TBL] [Abstract][Full Text] [Related]
3. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917 [TBL] [Abstract][Full Text] [Related]
5. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Kiura K; Imamura F; Kagamu H; Matsumoto S; Hida T; Nakagawa K; Satouchi M; Okamoto I; Takenoyama M; Fujisaka Y; Kurata T; Ito M; Tokushige K; Hatano B; Nishio M Jpn J Clin Oncol; 2018 Apr; 48(4):367-375. PubMed ID: 29474558 [TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy of Alectinib in Patients with Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835 [TBL] [Abstract][Full Text] [Related]
7. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430 [TBL] [Abstract][Full Text] [Related]
8. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. Nishio M; Murakami H; Horiike A; Takahashi T; Hirai F; Suenaga N; Tajima T; Tokushige K; Ishii M; Boral A; Robson M; Seto T J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125 [TBL] [Abstract][Full Text] [Related]
9. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571 [TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Wu YL; Shi Y; Tan DSW; Xiaoqing L; Cheng Y; Zhou J; An TT; Lu Y; Zhu B; Bai C; Passos VQ; Lau YY; Xun L; Zhang L Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379 [TBL] [Abstract][Full Text] [Related]
11. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983 [TBL] [Abstract][Full Text] [Related]
12. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
13. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E; Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009 [TBL] [Abstract][Full Text] [Related]
15. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis. Fan J; Fong T; Xia Z; Zhang J; Luo P Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699 [TBL] [Abstract][Full Text] [Related]
17. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review. Zhao X; Feng Z; Wang G; Pang H; Wang M Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011 [TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. Carlson JJ; Canestaro W; Ravelo A; Wong W J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433 [TBL] [Abstract][Full Text] [Related]
19. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis. Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]